Intracranial Venous Stenting Evaluation in Patients With Idiopathic Intracranial Hypertension in the Early Phase

Inclusion Criteria: 1. Subject is ≥ 18 years old at inclusion. 2. Subject with definite new diagnosis (˂ 3 months) of IIH satisfying the modified Dandy criteria (A to E) 3. Subject with intracranial TVS stenosis on dominant transverse sinus and hypoplastic contralateral one (or bilateral TVS stenosis) diagnosed on MRI 4. Normal MRI findings excepted intracranial TVS stenosis or IIH related abnormalities 5. Subject with ophthalmologic IIH symptoms and signs (RNFL ≥ 130 µm, Frisen score ≥ 2, and absence of differential diagnostic) 6. Subject without macular ganglion cells atrophy seen on OCT 7. Patient having received information about data collection and having signed and dated an Informed Consent Form 8. Subjects must be able to attend all scheduled visits and to comply with all trial procedures 9. Subjects must be covered by public health insurance Exclusion Criteria: 1. Subject previously treated with acetazolamide for IIH 2. Known contrast product, Nickel, titanium allergy 3. Exposure to an oral drug, substance, or disorder that has been associated with elevation of intracranial pressure within 2 months of diagnosis (lithium, vitamin A, tetracycline and related compounds) 4. History of intracranial venous thrombosis or intracranial neoplasia 5. Fulminant decrease of visual acuity due to the IIH defined as a visual loss (of the most seriously impaired eye) of at least 3/10 (from corrected vision) within 4 weeks, in absence of any other ophthalmologic pathology and Mean Deficit of visual field superior to -10 dB 6. Macular ganglion cells atrophy seen on OCT 7. Optic nerve atrophy 8. Amblyopia 9. Refractive error greater ±8 sphere or more than ±3 in cylinder in either eye if there are abnormalities in funduscopy (optic disc tilt, staphyloma), previous glaucoma, other disorders causing visual loss 10. Pregnancy: if a woman is of childbearing potential a urine or serum beta HCG test is positive 11. Patient with a severe or fatal comorbidity that will likely prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient. 12. Evidence of intracranial hemorrhage (subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), etc.) 13. Life expectancy under 6 months 14. Chronic IIH 15. Patients with renal failure (creatinine \> 1.5 mg/dl and/or creatinine clearance \< 60 mL/min, except if patient is already on hemodialysis) 16. History of previously implanted intra-cranial sinus stent 17. Previous gastric bypass surgery 18. Contra-indication to general anesthesia 19. Contra-indication to aspirin, clopidogrel or other P2Y12 anti-aggregant 20. History of chronic obstructive pulmonary disease or other severe respiratory disease 21. History of deep vein thrombosis or pulmonary embolism 22. History of atrial fibrillation or other risks of stroke 23. Cerebral vascular lesions (arteriovenous malformation, arteriovenous fistula, aneurysms, significant stenosis of extra- or intra-cranial vessels other than the targeted venous sinus stenosis, intracranial artery dissection, etc.). 24. Anatomical anomaly of the venous sinus which would prevent safe catheterization and stenting 25. Subject who are in a dependency or employment with the sponsor or the investigator 26. Participation in another clinical trial or administration of an unapproved drug within the last 4 weeks before the screening date 27. Subject protected according to the French Public Health Code (e.g. patients under law protection, prisoners, pregnant, parturient or lactating women, and patients under guardianship/curatorship)